Necrotizing periodontitis or medication-related osteonecrosis of the jaw (MRONJ) in a patient receiving Bemcentinib—a case report
Sign Up to like & getrecommendations! Published in 2020 at "Oral and Maxillofacial Surgery"
DOI: 10.1007/s10006-020-00851-w
Abstract: Bemcentinib is a newly developed AXL inhibitor that is currently under investigation in phase II trails for the treatment of acute myeloblastic leukemia (AML). Clinical and radiographic findings in this case were very similar to… read more here.
Keywords: bemcentinib; necrotizing periodontitis; osteonecrosis jaw; medication related ... See more keywords
Abstract 3245: AXL as a therapeutic target in STK11 mutant NSCLC
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3245
Abstract: STK11 (LKB1) is a tumor suppressor, and loss-of-function mutations contribute to tumorigenesis. Mutations in the STK11 gene (STK11m) are present in ~ 20% of NSCLCs and are associated with poor response to chemotherapy and immune… read more here.
Keywords: bemcentinib; stk11; tumor; axl ... See more keywords
First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.7043
Abstract: 7043 Background: The RTK AXL represents a therapeutic target promoting AML cell proliferation and survival by pleiotropic mechanisms and is a negative regulator of anti-tumour immunity. Bemcentinib is a first-in-class, highly selective, oral AXL inhibitor… read more here.
Keywords: bemcentinib; axl; combination; aml ... See more keywords